IRulya Therapeutics Inc.
IRLAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeIRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. With a market capitalization of $33.6M, it sits in micro-cap territory. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Market Cap
$33.6M
Beta
1.33
P/E (TTM)
—
P/E (Fwd)
-7.06
EPS (TTM)
$-214.01
EPS (Fwd)
$-4.68
ROE
-153.8%
ROA
-31.5%
Cash
$116.0M
Total Debt
$0
Free CF
-$25.7M
52W Change
-90.6%
Annual Financials
Cash vs Debt
Where IRLA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, IRLA finished 29.21% above its 150-day moving average ($24.79) and 60.95% below its 200-day moving average ($82.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRLA overbought or oversold?
At the October 19, 2026 close, IRLA's RSI(14) was 56.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
IRulya Therapeutics Inc. reports $116.0M in cash and $0 in total debt. Free cash flow is running at -$25.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -153.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence IRulya Therapeutics Inc.'s trajectory.